HR Execs on the Move

Amway

www.amway.com

 
Amway is the world`s No. 1 direct selling business, according to the Direct Selling News Global 100. Established in 1959, with sales of $8.6 billion, Amway operates in more than 100 countries and territories. We manufacture and distribute 450+ consumer products that support health and well-being. More than 19,000 employees worldwide support millions of Amway Business Owners who sell Amway products. Headquartered in Ada, Michigan, Amway is a center of health, skincare and home product innovation and top-selling, global brands. In addition, we are a company committed to providing employees with challenging career opportunities, a comprehensive total rewards package, profit ...
  • Number of Employees: 5K-10K
  • Annual Revenue: > $1 Billion
  • www.amway.com
  • 7575 Fulton Street East
    Ada, MI USA 49355
  • Phone: 616.787.1000

Executives

Name Title Contact Details
Kevin Schrauben
 Vice President - Global Supply Chain Finance and Function FPandA Profile
Roy Kuennen
 Director - Durables R&D Profile
Bill Stoner
 Product Development Manager Profile
Jeff Renz
 VP - Product Management / Technology Profile
Kristi Pelc
 Vice President Of Product Development Profile

Similar Companies

HyHealth

HyHealth is a Toledo, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MediMedia, Inc

MediMedia, Inc is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in San Bruno, CA. To find more information about MediMedia, Inc, please visit www.medimedia.com

ilumed

ilumed is a company that helps providers, payers, and other healthcare organizations transition to value-based care models, which focus on quality of health outcomes rather than quantity of services.

Night Shift Radiology

Night Shift Radiology is a San Mateo, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Portola

Portola Pharmaceuticals is dedicated to developing and commercializing therapies that transform patient lives and advance patient care by changing treatment paradigms in thrombosis and other hematologic diseases. Our two lead assets are Bevyxxa® (betrixaban), and andexanet alfa. In addition, cerdulatinib is our investigational Syk/JAK inhibitor to treat hematologic cancers. These compounds come from our own internal research efforts and represent important advances to address significant unmet needs. We are employing novel strategies that may increase the likelihood of clinical, regulatory and commercial success of our potentially lifesaving therapies.